Crossing the bridge: tailoring antiviral prophylaxis by linking it to CMV-specific immunity
Why is CMV-specific immunity important? How can CMV-specific immunity be achieved?
Transplant patients, especially those post lung and heart transplantation, often suffer from CMV infection and/or disease. Most patients receive antiviral prophylaxis, yet many patients still develop late-onset CMV. Specific immunity to CMV can protect patients from CMV viremia and disease. However, this fact does not seem to be considered widely, nor the measures that can be taken to support the patient's immune system in building up immunity against CMV. By attending this ESOT and Biotest webinar, participants will learn how to evaluate CMV immunity and why CMV-specific immunity is so important for the long-term outcome of patients. Attendees will also learn how one can support the patient's immune system to build CMV-specific immunity through mTor inhibitors/everolimus and CMVIG.
this is part of the webinar series supported by Biotest via an unrestricted educational grant
ESOT: [ Ссылка ]
ESOT Congress: [ Ссылка ]
ESOT Transplant Live: [ Ссылка ]
#transplantation #education #ESOT4edu
